SEC Form 4 · accession 0001209191-15-043034
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Mendlein
Officer — CEO and Executive Chairman · Director
Period of report
May 12, 2015
Accepted (ET)
May 14, 2015 · 9:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 12, 2015 | C | 24,055 | — | A | 245,971 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Redeemable Convertible Preferred StockF1,F2 | — | May 12, 2015 | C | 170,218 | D | — | — | Common Stock | 21,400 | 0 | D |
| Series D Redeemable Convertible Preferred StockF1,F2 | — | May 12, 2015 | C | 21,122 | D | — | — | Common Stock | 2,655 | 0 | D |
Explanation of responses
- F1The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Person converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on a 1-for-7.95413 basis.
- F2Reflects a 1-for-7.95413 stock conversion of the Issuer's Preferred Stock into Common Stock which became effective immediately prior to the closing of the Issuer's initial public offering.